GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Financial Strength

Biovica International AB (OSTO:BIOVIC B) Financial Strength : 3 (As of Apr. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Financial Strength?

Biovica International AB has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Biovica International AB displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Biovica International AB did not have earnings to cover the interest expense. Biovica International AB's debt to revenue ratio for the quarter that ended in Apr. 2025 was 0.50. As of today, Biovica International AB's Altman Z-Score is -13.66.


Competitive Comparison of Biovica International AB's Financial Strength

For the Biotechnology subindustry, Biovica International AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's Financial Strength distribution charts can be found below:

* The bar in red indicates where Biovica International AB's Financial Strength falls into.


;
;

Biovica International AB Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Biovica International AB's Interest Expense for the months ended in Apr. 2025 was kr-0.25 Mil. Its Operating Income for the months ended in Apr. 2025 was kr-21.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2025 was kr1.74 Mil.

Biovica International AB's Interest Coverage for the quarter that ended in Apr. 2025 is

Biovica International AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Biovica International AB's Debt to Revenue Ratio for the quarter that ended in Apr. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Apr. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.915 + 1.736) / 9.328
=0.50

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Biovica International AB has a Z-score of -13.66, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -13.66 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Biovica International AB has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Biovica International AB Financial Strength Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines